Ongoing Clinical Trials for Older Critically Ill Patients
This article provides information about an ongoing clinical trial focused on older adults who are critically ill and require intensive care with breathing support. The trial is investigating whether early use of a specific sedative medication can improve survival and recovery outcomes in patients aged 65 and older who need mechanical ventilation in intensive care units.
Clinical trial locations
- Finland
- Germany
- Ireland
- Netherlands
Study on Early Sedation with Dexmedetomidine vs. Placebo for Older Critically Ill Patients on Ventilators
This clinical trial is examining whether early use of a sedative medication called Dexmedetomidine can improve outcomes for older patients in intensive care who require breathing support from mechanical ventilators. The study is being conducted across multiple European countries, including Finland, Germany, Ireland, and the Netherlands, and is expected to run until December 2025.
Who can participate:
- Patients must be 65 years of age or older
- They must be in an intensive care unit with a breathing tube inserted and connected to a mechanical ventilator
- Doctors expect they will need the breathing machine for at least the next two days
- They require immediate sedative medication to keep them comfortable and safe while receiving life support treatments
Who cannot participate:
The trial excludes certain critically ill patients based on specific medical needs, including those requiring medications to support heart function and blood pressure, and those needing particular pain relief or sedation medications beyond the study protocol.
What the trial is studying:
The main goal of this study is to evaluate whether using Dexmedetomidine as the primary sedative can improve 90-day survival rates in older critically ill patients. Researchers will compare patients receiving Dexmedetomidine with those receiving a placebo, which is an inactive substance with no medication.
The trial will also examine several other important outcomes, including:
- How many days patients are alive without experiencing confusion or coma within the first 28 days
- How many days patients are alive and breathing without the ventilator within 28 days
- Whether any major kidney problems develop within 28 days
- How long patients need to stay on the breathing machine
- The total length of hospital stay for those who survive
The investigational medication:
Dexmedetomidine is given as a solution through an intravenous infusion. It works by activating certain receptors in the brain that help calm patients and may reduce the need for other sedative medications. This trial aims to verify earlier findings that suggested potential benefits of using dexmedetomidine in older critically ill patients requiring breathing support.
The medication is administered as a concentrate for solution via infusion, while patients in the comparison group receive a placebo made of saline solution that looks identical but contains no active medication.
Summary
Currently, there is one ongoing clinical trial specifically designed for older critically ill patients requiring mechanical ventilation and intensive care. This international study spans four European countries: Finland, Germany, Ireland, and the Netherlands, demonstrating a coordinated European effort to address the care of this vulnerable patient population.
The trial focuses exclusively on evaluating Dexmedetomidine as an early sedation option for patients aged 65 and older in intensive care settings. The study addresses an important clinical question about whether this particular sedative medication can improve survival and reduce complications such as confusion, delirium, and kidney problems in older adults who are critically ill.
Recruitment for the trial began in August 2023, and the study is expected to conclude in December 2025. Patients and families interested in learning more about this trial should speak with their intensive care team to determine if participation might be appropriate.
